INCYTE CORP

Incyte Corporation reported strong third quarter 2026 financial results, with total revenue increasing 14% year-over-year to $1.56 billion and total net sales rising 14% to $1.32 billion. The company raised its full-year 2026 financial guidance for key products and segments. Significant pipeline progress was also highlighted, including positive Phase 1 data for INCB161734 and INCA033890, and the completion of the Vega Therapeutics acquisition in July.

Incyte Corporation reported strong second-quarter 2026 financial results, with total revenues increasing by 37.7% to $1.67 billion and net income rising by 44.6% to $585.6 million. Diluted EPS grew by 37.7% to $2.81. The company saw significant growth in net sales, particularly for OPZELURA, which benefited from an agreement with CMS, and launched JAKAFI XR. Operating cash flow also saw a substantial increase.

Incyte reported strong second-quarter 2026 financial results, with total revenue increasing 38% to $1.67 billion and total net sales up 40% to $1.49 billion. This growth was significantly boosted by a $246 million non-cash benefit from a CMS settlement related to Opzelura. The company raised its full-year 2026 total net sales guidance to $5.13-$5.26 billion, reflecting strong product performance and the CMS agreement. Incyte also completed the acquisition of Vega Therapeutics for $1.25 billion, adding latarcibart to its pipeline, and expects ten clinical data readouts in the second half of 2026.

Incyte Corporation announced the completion of its previously disclosed acquisition of Vega Therapeutics, Inc., a subsidiary of Star Therapeutics LLC. This acquisition significantly expands Incyte's hematology portfolio by adding VGA039, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease (VWD). Incyte paid $1.25 billion upfront, with Star Therapeutics eligible for up to an additional $750 million in sales milestones, and expects to record the transaction as a one-time R&D expense in the third quarter and full year 2026.

Incyte Corporation announced an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve litigation regarding Medicaid rebate rules for Opzelura cream. Under the settlement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi. The company expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026, and anticipates improved gross-to-net for Opzelura going forward.

Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion. Star Therapeutics could receive up to an additional $750 million in sales milestone payments. This acquisition will expand Incyte's hematology portfolio by adding VGA039, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease, which has received multiple FDA designations. The transaction is expected to close in the third quarter of 2026, pending regulatory approval, and will result in an R&D charge of approximately $1.25 billion.

Incyte Corporation announced its 2026 Annual Meeting of Shareholders will be held on June 8, 2026, to elect eight directors, approve executive compensation on an advisory basis, and ratify Ernst & Young LLP as the independent auditor. The company reported strong 2025 financial performance with net sales of $4.35 billion, a 20% year-over-year increase, driven by broad-based demand across its core business. Incyte also highlighted significant pipeline advancements, expecting 14 pivotal trials by the end of 2026.

Incyte Corp reported strong first-quarter 2026 financial results, with total revenues increasing by 20.9% to $1.27 billion and net income surging by 91.7% to $303.3 million. Diluted EPS rose to $1.47. The company also highlighted a favorable settlement with Novartis reducing JAKAFI royalty payments and an exclusive option agreement with Prelude Therapeutics for a JAK2V617F inhibitor program.

Incyte reported strong Q1 2026 financial results with total revenue increasing 21% to $1.27 billion and total net sales rising 20% to $1.10 billion year-over-year. The company saw significant growth in product sales, particularly Opzelura (+20%), Niktimvo (+305%), and Zynyz (+1,276%). Key business updates include positive Phase 3 results for povorcitinib in nonsegmental vitiligo, NDA acceptance for povorcitinib in hidradenitis suppurativa, and four anticipated approvals/launches from mid-2026 into early 2027. Incyte also reaffirmed its full-year 2026 financial guidance and announced new executive appointments.